A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Juno Therapeutics

Status: Enrolling

Conditions: Mantle Cell Lymphoma (MCL)

Treatments: Biological: Lisocabtagene maraleucel

Study type: Observational

Funder types: Industry

Identifiers

NCT06788652

CA082-1093

Details and patient eligibility

About

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA

Exclusion criteria

• Participants known to be participating in investigational studies at the time of liso-cel infusion.
• Participants treated with non-conforming CAR T-cell product.

Trial design

300 participants in 1 patient group

Participants treated with lisocabtagene maraleucel

Treatment:

Biological: Lisocabtagene maraleucel